1例索拉非尼治疗甲状腺癌致高血压亚急症的药学监护  

Pharmaceutical Care of One Case of Hypertension Urgency Caused by Sorafenib in the Treatment of Thyroid Cancer

作　　者：张婧[1] 李宝金[2] 谭俊[1] ZHANG Jing;LI Baojin;TAN Jun(Derpartment of Pharmacy,The Eighth People’s Hospital of Guangzhou,Guangzhou,Guangdong 510060,China;Department of Surgical,The Eighth People’s Hospital of Guangzhou,Guangzhou,Guangdong 510060,China)

机构地区：[1]广州市第八人民医院药剂科,广东广州510060 [2]广州市第八人民医院外科,广东广州510060

出　　处：《今日药学》2020年第3期201-203,共3页Pharmacy Today

摘　　要：目的探讨索拉非尼致高血压的特点、处理原则及药学监护。方法临床药师通过回顾国内外关于索拉非尼致高血压的文献,就此例患者的不良反应进行关联性分析,并实施药学干预和药学监护。结果此例患者在使用索拉非尼治疗近2周时出现高血压亚急症,及时停药并给予降压治疗后,患者血压可控制平稳,并继续索拉非尼治疗。结论临床药师应积极参与MDT模式下的靶向药物不良反应管理。发生索拉非尼相关性高血压时,应根据患者临床症状、高血压分级和用药史,采取合适的处理措施,最大化靶向药物的临床疗效。OBJECTIVE To investigate the characteristics,treatment principles and pharmaceutical care of hypertension caused by sorafenib.METHODS By reviewing the literatures on sorafenib-induced hypertension at home and abroad,clinical pharmacists analyzed the relationship evaluation of the adverse drug reaction,and implemented pharmaceutical intervention and pharmaceutical care.RESULTS This patient developed hypertension urgency after nearly 2 weeks of treatment with sorafenib,with timely withdrawal and antihypertensive treatment,the patient's blood pressure became stable and continued treatment with sorafenib.CONCLUSION Clinical pharmacists should actively participate in the MDT management of the adverse drug reaction of targeted drugs.When sorafenibinduced hypertension occurs,appropriate treatment measures should be taken according to patients'clinical symptoms,hypertension classification and medication history,so as to maximize the clinical effects of targeted drugs.

关 键 词：索拉非尼 甲状腺癌 高血压 药学监护 

分 类 号：R979.1[医药卫生—药品]